Kun-Hsing Yu, MD, PhD

Kun-Hsing Yu, MD, PhD

Associate Professor of Biomedical Informatics, Harvard Medical School
Assistant Professor of Pathology, Brigham and Women's Hospital
Instructor in Epidemiology, Harvard T.H. Chan School of Public Health
Yu Lab

Kun-Hsing "Kun" Yu received his PhD in Biomedical Informatics and PhD Minor in Computer Science from Stanford University, and he obtained his MD from National Taiwan University, Taiwan. His research focuses on the integration of quantitative histopathology image patterns with multi-omics (genomics, epigenomics, transcriptomics, and proteomics) profiles to advance cancer research and clinical practice. His team has developed fully-automated algorithms to analyze whole-slide histopathology images at scale, discovered the molecular mechanisms underpinning the microscopic phenotypes of tumor cells, and identified novel cellular morphologies for patient prognosis. His research interests include quantitative pathology, machine learning, and translational bioinformatics.

DBMI Research Areas
DBMI Courses
Current Postdoctoral Fellowship Opportunities
Association of Race and Socioeconomic Disadvantage With Missed Telemedicine Visits for Pediatric Patients During the COVID-19 Pandemic.
Authors: Brociner E, Yu KH, Kohane IS, Crowley M.
JAMA Pediatr
View full abstract on Pubmed
Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia.
Authors: Lu C, Jin D, Palmer N, Fox K, Kohane IS, Smoller JW, Yu KH.
Transl Psychiatry
View full abstract on Pubmed
Outdoor mass gathering events and SARS-CoV-2 infection in Catalonia (North-East Spain).
Authors: Miron O, Yu KH.
Lancet Reg Health Eur
View full abstract on Pubmed
Ten quick tips for deep learning in biology.
Authors: Lee BD, Gitter A, Greene CS, Raschka S, Maguire F, Titus AJ, Kessler MD, Lee AJ, Chevrette MG, Stewart PA, Britto-Borges T, Cofer EM, Yu KH, Carmona JJ, Fertig EJ, Kalinin AA, Signal B, Lengerich BJ, Triche TJ, Boca SM.
PLoS Comput Biol
View full abstract on Pubmed
Integrative multiomics-histopathology analysis for breast cancer classification.
Authors: Ektefaie Y, Yuan W, Dillon DA, Lin NU, Golden JA, Kohane IS, Yu KH.
NPJ Breast Cancer
View full abstract on Pubmed
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.
Authors: Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, Yu KH, Kou SC.
NPJ Precis Oncol
View full abstract on Pubmed
Classification of glioblastoma versus primary central nervous system lymphoma using convolutional neural networks.
Authors: McAvoy M, Prieto PC, Kaczmarzyk JR, Fernández IS, McNulty J, Smith T, Yu KH, Gormley WB, Arnaout O.
Sci Rep
View full abstract on Pubmed
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma.
Authors: Marostica E, Barber R, Denize T, Kohane IS, Signoretti S, Golden JA, Yu KH.
Clin Cancer Res
View full abstract on Pubmed
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Authors: Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR.
J Am Acad Dermatol
View full abstract on Pubmed
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Authors: Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR.
J Immunother Cancer
View full abstract on Pubmed